Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRITON-CM study of nucresiran in transthyretin amyloidosis with cardiomyopathy
NL-OMON59175Phase 3Recruiting
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Dec 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in transthyretin amyloidosis (ATTR) comparing nucresiran with placebo (2 arms). Primary endpoint: Composite outcome of all-cause mortality and recurrent cardiovascular events. Started Dec 2025; status: recruiting.
02
Drugs
nucresiran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NL-OMON59175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59175.